X4 Pharmaceuticals (NASDAQ:XFOR) PT Raised to $5.00

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective hoisted by equities researchers at HC Wainwright from $3.00 to $5.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 352.49% from the stock’s previous close.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $1.11 on Tuesday. X4 Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.58. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.34 and a current ratio of 5.34. The stock has a market capitalization of $185.57 million, a PE ratio of -1.84 and a beta of 0.49. The stock has a 50-day simple moving average of $1.15 and a 200 day simple moving average of $0.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.05. Research analysts anticipate that X4 Pharmaceuticals will post -0.47 EPS for the current year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the transaction, the chief executive officer now owns 765,068 shares of the company’s stock, valued at approximately $673,259.84. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Adam S. Mostafa sold 52,500 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 49,678 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the transaction, the chief executive officer now directly owns 765,068 shares of the company’s stock, valued at $673,259.84. The disclosure for this sale can be found here. Insiders sold a total of 185,708 shares of company stock valued at $170,428 in the last quarter. Corporate insiders own 1.08% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its position in X4 Pharmaceuticals by 38.8% during the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after acquiring an additional 13,328 shares during the last quarter. Barclays PLC grew its position in X4 Pharmaceuticals by 334.8% during the 3rd quarter. Barclays PLC now owns 382,134 shares of the company’s stock worth $417,000 after acquiring an additional 294,255 shares during the last quarter. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals in the 3rd quarter valued at $678,000. Stonepine Capital Management LLC boosted its position in X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock valued at $5,748,000 after buying an additional 668,422 shares during the last quarter. Finally, Kingdon Capital Management L.L.C. boosted its position in X4 Pharmaceuticals by 76.0% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after buying an additional 1,500,000 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.